The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Usain it says news next week
A 24-bed quarantine clinic in Whitechapel, London, has been earmarked for the initial challenge trials. It is run by hVivo, a spinout from Queen Mary University of London that was bought this year by Open Orphan, a Dublin-based pharmaceutical research organisation. Imperial College London is the project’s academic leader.
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/b782f666-6847-4487-986c-56d3f5e46c0b
A 24-bed quarantine clinic in Whitechapel, London, has been earmarked for the initial challenge trials. It is run by hVivo, a spinout from Queen Mary University of London that was bought this year by Open Orphan, a Dublin-based pharmaceutical research organisation. Imperial College London is the project’s academic leader.
https://www.ft.com/content/b782f666-6847-4487-986c-56d3f5e46c0b
......and Open Orphan!
Not Orph but hVivo mentiond - definitely us. Will be announced next week.
need a subscription to read that. Key points/Orph mentioned?
thanks
World News Folks:
https://www.ft.com/content/b782f666-6847-4487-986c-56d3f5e46c0b